These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 13510553)

  • 21. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria.
    Mejia P; Davis AE
    Shock; 2012 Aug; 38(2):220-5. PubMed ID: 22576004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of two types of internal core structures of gram-negative bacteria lipopolysaccharides using chromophore markers].
    Dmitriev BA; Lapina EB; Murashko EA
    Bioorg Khim; 1991 Apr; 17(4):482-5. PubMed ID: 1888341
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of lipopolysaccharide of gram-negative bacilli in sensitivity and resistance to serum.
    Porat R; Johns MA; McCabe WR
    Prog Clin Biol Res; 1988; 272():103-14. PubMed ID: 2455915
    [No Abstract]   [Full Text] [Related]  

  • 24. Self and nonself recognition with bacterial and animal glycans, surveys by synthetic chemistry.
    Fujimoto Y; Tanaka K; Shimoyama A; Fukase K
    Methods Enzymol; 2010; 478():323-42. PubMed ID: 20816488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Limulus lysate activity of some organisms resided in oral cavity].
    Wang KF
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Jan; 27(1):37-8, 62. PubMed ID: 1499397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lipopolysaccharides of gram negative bacilli on the rat litter in utero.
    THIERSCH JB
    Proc Soc Exp Biol Med; 1962 Feb; 109():429-37. PubMed ID: 13920675
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of various lipopolysaccharides of gram-negative bacteria on the macrophage activity, oxidative metabolism, and liver microsomal activity].
    Sibiriak SV; Sergeeva SA; Khlopushina TG; Kurchatova NN; Iusupova RSh
    Biull Eksp Biol Med; 1998 Feb; 125(2):183-6. PubMed ID: 9559133
    [No Abstract]   [Full Text] [Related]  

  • 28. [Role of bacterial lipopolysaccharides in human diseases: evolution of outlook].
    Malov VA; Pak SG
    Vestn Ross Akad Med Nauk; 1997; (8):33-8. PubMed ID: 9340047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotropic properties of lipopolysaccharides of gram-negative bacteria].
    Sibiriak SV; Alekhin EK
    Antibiot Khimioter; 1988 Nov; 33(11):871-7. PubMed ID: 3265865
    [No Abstract]   [Full Text] [Related]  

  • 30. Lipopolysaccharide: Biosynthetic pathway and structure modification.
    Wang X; Quinn PJ
    Prog Lipid Res; 2010 Apr; 49(2):97-107. PubMed ID: 19815028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Structure of lipopolysaccharides from gram-negative bacteria. II. Core structure (Review)].
    Knirel' IuA; Kochetkov NK
    Biokhimiia; 1993 Feb; 58(2):182-201. PubMed ID: 8485212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shield as signal: lipopolysaccharides and the evolution of immunity to gram-negative bacteria.
    Munford RS; Varley AW
    PLoS Pathog; 2006 Jun; 2(6):e67. PubMed ID: 16846256
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of lipid A in phagocytosis of gram-negative bacteria and their lipopolysaccharides.
    Hofman J; Dlabac V
    J Hyg Epidemiol Microbiol Immunol; 1974; 18(4):447-53. PubMed ID: 4616056
    [No Abstract]   [Full Text] [Related]  

  • 34. Both membrane-bound and soluble forms of CD14 bind to gram-negative bacteria.
    Jack RS; Grunwald U; Stelter F; Workalemahu G; Schütt C
    Eur J Immunol; 1995 May; 25(5):1436-41. PubMed ID: 7539760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of bacterial lipopolysaccharides with serum proteins.
    Ulevitch RJ; Tobias PS
    Prog Clin Biol Res; 1988; 272():309-18. PubMed ID: 2455916
    [No Abstract]   [Full Text] [Related]  

  • 36. Transcriptomic response of immune signalling pathways in intestinal epithelial cells exposed to lipopolysaccharides, Gram-negative bacteria or potentially probiotic microbes.
    Audy J; Mathieu O; Belvis J; Tompkins TA
    Benef Microbes; 2012 Dec; 3(4):273-86. PubMed ID: 23234729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls.
    Vigsnæs LK; Brynskov J; Steenholdt C; Wilcks A; Licht TR
    Benef Microbes; 2012 Dec; 3(4):287-97. PubMed ID: 22968374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of fluid phase C1/C1q and macrophage membrane-associated C1q with gram-negative bacteria.
    Clas F; Euteneuer B; Stemmer F; Loos M
    Behring Inst Mitt; 1989 Jul; (84):236-54. PubMed ID: 2552981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lipopolysaccharides in gram negative bacteria].
    Ciznár I; Krcméry V
    Lek Veda Zahr; 1967 Jan; 1():17-21. PubMed ID: 5342661
    [No Abstract]   [Full Text] [Related]  

  • 40. [New approach to an increase of specificity in determination of antibodies to lipopolysaccharides of Gram-negative bacteria by solid-phase enzyme-linked immunosorbent assay].
    Gordienko AI
    Ukr Biokhim Zh (1999); 2004; 76(6):130-5. PubMed ID: 16350757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.